Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia

Type 1 Diabetes Clinical Trial

Official title:

Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02700048
• Other study ID #: 1103M96932
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: June 2016
• Est. completion date: July 2021

Study information

• Verified date: March 2023
• Source: University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single center, single-blind randomized cross over design trial that will compare the impact of intra-nasal naloxone vs. intra-nasal saline administration during experimental hypoglycemia on day one on responses to experimental hypoglycemia on day two. Investigators intend to enroll 18 individuals to obtain the complete data sets from 15 participants. Expected duration of subject participation is 10-12 weeks. This study will consist of two 2-day intervention visits separated by approximately 8 weeks.

Description:

This is a single center, single-blinded randomized cross over design trial, that will compare the impact of IN naloxone vs. IN saline during experimental hypoglycemia on day one on the responses to experimental hypoglycemia on day two. 18 participants will be studied twice, 8 weeks apart. On each occasion participants will undergo a 2 hour hypoglycemic clamp (target 50 mg/dl) in the morning and in the afternoon on day one and then again on the morning of day 2. During the morning clamps, samples will be collected for later measurement of serum epinephrine, glucagon and cortisol levels and participants will be asked to complete a hypoglycemia symptom questionnaire. 3 intranasal doses (4 mg each) of naloxone hydrochloride or IN saline will be administered to the subject on day 1. Plasma will be collected for measurement of naloxone concentrations on day 1 primary outcome is the difference in peak epinephrine secretion during the morning episodes of hypoglycemia on days one and two, thus each participant will have two observations: one from their naloxone experiment and one from their saline experiment. Secondary endpoint will be naloxone pharmacokinetics including maximum concentration (Cmax), time to maximum concentration (Tmax) and area under the curve (AUC)

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: July 2021
• Est. primary completion date: July 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Subjects are capable of giving informed consent.

2. Female subjects must be post-menopausal for at least 1 year, or surgically incapable of bearing children, or practicing at least one or more of the following methods of contraception for three months prior to, and during the study: hormonal, intrauterine device (IUD), or barrier method in combination with a spermicide.

3. Subject should be medication free, other than hormonal birth control, for 48 hours before through 24 hours after study drug administration. If the need for medication is identified during this time period, it will be discussed with and approved by the PI.

Exclusion Criteria:

1. Women who are pregnant.

2. Women who are breastfeeding.

3. Subject has a known hypersensitivity to naloxone.

4. Subject with hypertension

5. Subject has a significant history of cardiac, neurologic, psychiatric, oncologic, endocrine, metabolic, renal or hepatic disease

6. Subject has taken or used any investigational drug or device in the 30 days prior to screening.

7. Subject has taken either prescribed or over the counter medication for 48 hours prior to study drug administration on either of the study days, other than hormonal birth control.

8. History of narcotic or heroin abuse.

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Hypoglycemia
• Hypoglycemia Unawareness
• Type 1 Diabetes
• Unconsciousness

Intervention

Drug:
• intra-nasal naloxone
3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
• Intra-nasal saline
3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps

Locations

Country	Name	City	State
United States	Clinical and Translational Science Institute, University of Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Within Person Difference in Peak Epinephrine During Hypoglycemia	Primary endpoint will be the within person difference in peak epinephrine secretion during the morning episodes of hypoglycemia on days one and two; investigators will compare this difference between the two treatment conditions	2 years
Secondary	Naloxone Pharmacokinetics	maximum concentration (Cmax)	2 year
Secondary	Naloxone Pharmacokinetics	area under the curve (AUC)	2 year